摘要
目的探讨两种新辅助化疗对乳腺癌临床治疗的疗效。方法 70例乳腺癌中晚期患者作为研究对象,通过随机数字表法将其分为研究组与对照组,各35例。对照组患者采取TAC(多西他赛+吡柔比星+环磷酰胺)方案进行新辅助化疗,研究组患者采取TEC(多西他赛+表柔比星+环磷酰胺)方案进行新辅助化疗,比较两组患者的临床疗效以及不良反应发生情况。结果研究组患者总有效率为88.6%,对照组为82.9%,两组总有效率比较差异无统计学意义(P>0.05);研究组患者不良反应发生率与对照组患者比较,差异无统计学意义(P>0.05)。结论两种新辅助化疗方案治疗乳腺癌具有显著的疗效,且不良反应发生率低,值得在临床上推广及应用。
Objective To investigate curative effect by two neoadjuvant chemotherapy measures in clinical treatment of breast cancer. Methods A total of 70 patients with moderate and advanced breast cancer as study subjects were divided by random number table into research group and control group, with 35 cases in each group. The control group received TAC（docetaxel＋pirarubicin＋cyclophosphamide） regimen for neoadjuvant chemotherapy, while the research group received TEC（docetaxel＋epirubicin＋cyclophosphamide） regimen for neoadjuvant chemotherapy. Clinical effects and adverse reactions were compared between the two groups. Results The research group had total effective rate as 88.6%, which was 82.9% in the control group. There was no statistically significant difference of total effective rate between the two groups（P〉0.05）. The difference of incidence of adverse reactions had no statistical significance between the two groups（P〉0.05）. Conclusion Both neoadjuvant chemotherapy measures contains precisely curative effect, along with low incidence of adverse reactions. It is worth clinical promotion and application.
作者
林丹
LIN Dan.(Breast Center, Chaozhou City People＇s Hospital, Chaozhou 521000, China)
出处
《中国实用医药》
2016年第29期26-28,共3页
China Practical Medicine
关键词
新辅助化疗
乳腺癌
疗效
Neoadjuvant chemotherapy
Breast cancer
Curative effect
